Breaking Business News: Crown Laboratories to Buy Revance Therapeutics in $924 Million Merger Deal
Crown Laboratories, Inc. and Revance Therapeutics, Inc. are merging. Under the terms of the agreement, which has been unanimously approved by Revance’s Board of Directors, Crown will commence a tender offer to acquire all outstanding shares of Revance’s common stock for $6.66 per share in cash, representing a total enterprise value of $924 million. The purchase price represents […]